Kumar_1989_Int.J.Clin.Pharmacol.Ther.Toxicol_27_478

Reference

Title : Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease - Kumar_1989_Int.J.Clin.Pharmacol.Ther.Toxicol_27_478
Author(s) : Kumar V , Becker RE
Ref : Int J Clinical Pharmacology & Therapeutics Toxicol , 27 :478 , 1989
Abstract :

Tetrahydroaminoacridine (THA) was administered to a small number of patients with Alzheimer's disease. A minority of patients received the drug for longer than one week. Only one investigator [Summers et al. 1986] has reported dramatic palliative effects from the administration of THA. All investigators other than Summers reported side effects, especially troublesome is the frequent appearance of indications of hepatotoxicity. The efficacy and safety of THA are unknown. There is evidence that THA may have complex modes of action in addition to the inhibition of cholinesterases. There is a need for careful clinical assessment of THA and for further investigation of possible mechanisms of action.

PubMedSearch : Kumar_1989_Int.J.Clin.Pharmacol.Ther.Toxicol_27_478
PubMedID: 2684868

Related information

Citations formats

Kumar V, Becker RE (1989)
Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease
Int J Clinical Pharmacology & Therapeutics Toxicol 27 :478

Kumar V, Becker RE (1989)
Int J Clinical Pharmacology & Therapeutics Toxicol 27 :478